|Articles|April 1, 2005

Managing the Costs of Injectable Therapies: Do You Have the Right Game Plan? (PDF)

About three years ago I asked a large group of health plan executives if they knew how much they spend annually for ?specialty pharmacy? products. Few could respond, and virtually none had launched any efforts to control the then unknown rapid increase in these costs.Today, this is not the case.

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Subscribe

Latest CME

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Managing the Costs of Injectable Therapies: Do You Have the Right Game Plan? (PDF)

Related Content

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

8 things you need to understand about tariffs on pharmaceuticals and other healthcare products after last week’s Supreme Court ruling

7 things you need to know about the PBM reforms signed into law this week

Latest CME

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

27th Annual International Lung Cancer Congress®

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Trending on Managed Healthcare Executive

Eric Levine, M.P.H., on Medicaid work requirement exemptions and ADLs

New cholesterol guideline expands treatment eligibility to 55% of U.S. adults

FDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1

Acute pain drug Journavx helps drive Vertex growth in second quarter

Study shows atopic dermatitis increases shingles risk